{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:33:56Z","timestamp":1783528436903,"version":"3.55.0"},"reference-count":40,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharm. Pat. Anal."],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.4155\/ppa-2023-0015","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T14:02:28Z","timestamp":1696600948000},"page":"143-149","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Drug Repurposing of Mito-Atovaquone for Cancer Treatment"],"prefix":"10.1080","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-374X","authenticated-orcid":false,"given":"Nemesio","family":"Villa-Ruano","sequence":"first","affiliation":[{"name":"Direcci\u00f3n de Innovaci\u00f3n y Transferencia de Conocimiento\rBenem\u00e9rita Universidad Aut\u00f3noma de Puebla\rPuebla CP 72570\rM\u00e9xico"},{"name":"Consejo Nacional de Ciencia y Tecnolog\u00eda\rC\u00e1tedras CONACYT\rM\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3193-3730","authenticated-orcid":false,"given":"Maricruz","family":"Anaya-Ruiz","sequence":"additional","affiliation":[{"name":"Laboratorio de Biolog\u00eda Celular\rCentro de Investigaci\u00f3n Biom\u00e9dica de Oriente\rInstituto Mexicano del Seguro Social\rMetepec\rPuebla CP 74360\rM\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4130-9595","authenticated-orcid":false,"given":"Luis","family":"Villafa\u00f1a-Diaz","sequence":"additional","affiliation":[{"name":"Posgrado en Planeaci\u00f3n Estrat\u00e9gica y Direcci\u00f3n Tecnol\u00f3gica\rUniversidad Popular Aut\u00f3noma del Estado de Puebla\rPuebla CP 72410\rM\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-362X","authenticated-orcid":false,"given":"Diana","family":"Barron-Villaverde","sequence":"additional","affiliation":[{"name":"Posgrado en Planeaci\u00f3n Estrat\u00e9gica y Direcci\u00f3n Tecnol\u00f3gica\rUniversidad Popular Aut\u00f3noma del Estado de Puebla\rPuebla CP 72410\rM\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-2000","authenticated-orcid":false,"given":"Martin","family":"Perez-Santos","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Innovaci\u00f3n y Transferencia de Conocimiento\rBenem\u00e9rita Universidad Aut\u00f3noma de Puebla\rPuebla CP 72570\rM\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2017.3601"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/534314a"},{"key":"e_1_3_6_5_1","first-page":"e001509","article-title":"Exploring the repurposing potential of telmisartan drug in breast cancer: an in-silico and in-vitro approach","author":"Kumar U","year":"2023","unstructured":"Kumar U , AichJ , DevarajanS. Exploring the repurposing potential of telmisartan drug in breast cancer: an in-silico and in-vitro approach. Anticancer Drugse001509 (2023).","journal-title":"Anticancer Drugs"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021334"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010055"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-022-00944-x"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.4103\/0022-3859.81870"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112972"},{"key":"e_1_3_6_11_1","unstructured":"Hudson AT RandallAW. The Wellcome Foundation. England. Naphthoquinone derivatives. European patent EP0123238. 31 Oct 1984."},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1128\/EC.4.8.1483-1492.2005"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parint.2014.09.011"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2022.108354"},{"issue":"7","key":"e_1_3_6_15_1","first-page":"62","article-title":"Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration","volume":"7","author":"Cotton D","year":"1995","unstructured":"Cotton D . Atovaquone (Mepron) suspension approved by FDA. Food and Drug Administration. AIDS Clin. Care7(7), 62 (1995).","journal-title":"AIDS Clin. Care"},{"issue":"31","key":"e_1_3_6_16_1","first-page":"4177","article-title":"Atovaquon\/proguanil. Profylakse og behandling af malaria [Atovaquone\/proguanil. Prophylaxis and treatment of malaria]","volume":"162","author":"Lundgren JD","year":"2000","unstructured":"Lundgren JD , DragstedUB. Atovaquon\/proguanil. Profylakse og behandling af malaria [Atovaquone\/proguanil. Prophylaxis and treatment of malaria]. Ugeskr Laeger162(31), 4177\u20134181 (2000).","journal-title":"Ugeskr Laeger"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1752193"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041344"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153529"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14060521"},{"key":"e_1_3_6_21_1","unstructured":"Kalyanaraman B ChengG HardyMJ. Medical College of Wisconsin & Aix-Marseille Universit\u00e9 United States & France. Mitochondria-targeted atovaqone: a more potent and more effective antitumor antimicrobial and antimalarial drug. United States US2023017373. 19 January 2023."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74808-0"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101267"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08984-6"},{"key":"e_1_3_6_25_1","unstructured":"David J . Elevaid Therapeutics. United States. Use of atovaquone and proguanil for treatment of gastrointestinal diseases and inflammation. United States patent WO2021252371. 16 December 2021."},{"key":"e_1_3_6_26_1","unstructured":"Fliri AFJ . Systamedic. United States. Host directed drug combinatios for treatment of viral infections. United States patent WO2022261189. 15 December 2022."},{"key":"e_1_3_6_27_1","unstructured":"Li Ch-J . Globe Health Inst Nanjing. China. New combination drug for treating coronavirus infections pharmaceutical composition and use thereof. Worldwide patent WO2023040990. 23 March 2023."},{"key":"e_1_3_6_28_1","unstructured":"Frank D YeD. Dana-Farber Cancer Institute. E methods of treating cancer with atovaquone-related compounds. United States methods of treating cancer with atovaquone-related compounds. United States patent US2016296480. 13 October 2016."},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000499"},{"key":"e_1_3_6_30_1","unstructured":"Frank D YeD. Dana-Farber Cancer Institute. Enhanced immunotherapy of cancer using targeted transcriptional modulators. United States patent US2020230135. 23 July 2020."},{"issue":"6","key":"e_1_3_6_31_1","first-page":"1746","article-title":"Cell Cycle Arrest and Apoptosis Induced by Atovaquone in Non-Hodgkin's Lymphoma Raji Cells","volume":"30","author":"Chen CY","year":"2022","unstructured":"Chen CY , ShenX , XingSet al. Cell Cycle Arrest and Apoptosis Induced by Atovaquone in Non-Hodgkin's Lymphoma Raji Cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi30(6), 1746\u20131751 (2022).","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.9416"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02643-3"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092297"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-021-00871-x"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4128"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-1286"},{"issue":"9","key":"e_1_3_6_38_1","first-page":"1697","article-title":"Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma","volume":"8","author":"Gao X","year":"2018","unstructured":"Gao X , LiuX , ShanWet al. Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma. Am. J. Cancer Res.8(9), 1697\u20131711 (2018).","journal-title":"Am. J. Cancer Res."},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.22195"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.06.005"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.06.049"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10863-018-9755-y"}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/ppa-2023-0015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:31:57Z","timestamp":1715977917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/ppa-2023-0015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.4155\/ppa-2023-0015"],"URL":"https:\/\/doi.org\/10.4155\/ppa-2023-0015","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"value":"2046-8954","type":"print"},{"value":"2046-8962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}